Biolegend, 110728, PerCP/Cyanine5.5 anti-mouse CD45.1 Antibody, 100μg

CD45.1 is an alloantigen of CD45, expressed by Ly5.1 bearing mouse strains (e.g., RIII, SJL/J, STS/A, DA). CD45, a member of the protein tyrosine phosphatase (PTP) family, is a 180-240 kD glycoprotein expressed on all hematopoietic cells except mature erythrocytes and platelets. There are multiple isoforms in mice that play key roles in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation states of the cell as well as specific cell types. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.
100μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: SJL mouse thymocytes and splenocytes
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
Concentration: 0.2 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application. * PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.
Excitation Laser: Blue Laser (488 nm)
Application Notes: The A20 antibody does not react with leukocytes or mouse cells expressing the CD45.2 alloantigen. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation3, in vitro blocking of B cell responses1,2, immunohistochemical staining of frozen sections: OCT embedded7 and acetone-fixed4-6 (direct immunofluorescence detection with fluorochrome conjugated A20 was used in (5) and (6)).
Application References(PubMed link indicates BioLegend citation): Yakura H, et al. 1983. J. Exp. Med. 157:1077. (Block) Yakura H, et al. 1986. J. Immunol. 136:2729. (Block) Shen FW, et al. 1986. Immunogenetics 24:146. (IP) Suzuki K, et al. 2000. Immunity 13:691. (IHC-F) Werner N, et al. 2002. Arterioscler. Thromb. Vasc. Biol. 22:1567. (IHC-F) Lessner SM, et al. 2002. Am. J. Pathol. 160:2145. (FC, IHC-F) Chen CC, et al. 2005. P. Natl. Acad. Sci. USA 102:11408 (IHC-F) Pascal V, et al. 2007. J. Immunol. 179:1751. (FC) Mende I, et al. 2006. Blood 107:1383. (IHC-F, FC) Phan TG, et al. 2007. Nature Immunol. 8:992. (FC) Wither DR, et al. 2009. J. Immunol. 183:5079. PubMed Pascal V, et al.2007. J. Immunol. 179:1751. PubMed Lee SW, et al. 2009. J. Immunol. 182:6753. PubMed Takada K, et al. 2009. J. Exp Med. 206:2253. PubMed Beamer CA, et al. 2007. Am. J. Respir. Cell. Mol. Biol. 37:729. (FC) PubMed Li LX, et al. 2010. J. Immunol. 184:1728. PubMed Hosoi A, et al. 2008. Cancer Res. 68:3941. (FC) PubMed Kenna TJ, et al. 2008. Blood 111:2091. PubMed Kohlmeier JE, et al. 2008. Immunity. 29:101. (FC) PubMed
Product Citations: Hirai T, et al. 2020. Immunity. 54(1):84-98.e5. PubMed Tas JMJ, et al. 2022. Immunity. 55:1856. PubMed Melzi E, et al. 2022. Immunity. 55:2168. PubMed Russler-Germain EV, et al. 2021. Immunity. 54:2547. PubMed Brog RA, et al. 2022. Cancer Immunol Res. 10:962. PubMed Wang Y, et al. 2022. Cell Rep. 41:111738. PubMed Pleuger C, et al. 2022. Elife. 11: . PubMed Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed Li X, et al. 2022. Cell. 185:1709. PubMed Reticker-Flynn NE, et al. 2022. Cell. 185:1924. PubMed Wang L, et al. 2019. Cell Rep. 29:1848. PubMed Xia S, et al. 2014. J Leukoc Biol. 95:733. PubMed Turner JS et al. 2018. Cell reports. 25(6):1395-1403 . PubMed Stewart I et al. 2018. Immunity. 49(3):477-489 . PubMed Sangesland M, et al. 2020. Immunity. 51(4):735-749. PubMed Duan Q, et al. 2021. Front Cell Dev Biol. 9:761193. PubMed Hirano KI, et al. 2021. eLife. 0.416666666666667. PubMed Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed Liang Y, et al. 2020. J Immunol. 204:2984. PubMed Fuster JJ, et al. 2020. Cell Rep. 33:108326. PubMed Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed Inoue D, et al. 2021. Nat Genet. 53:707. PubMed Zong L, et al. 2021. NPJ Aging Mech Dis. 7:25. PubMed Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed Marangoni F, et al. 2021. Cell. . PubMed Yoshimi A, et al. 2019. Nature. 574:273. PubMed Beauchamp EM, et al. 2021. Blood Cancer Discov. 6:. PubMed Liu D et al. 2019. Immunity. 51(1):64-76 . PubMed Chen X et al. 2017. Cell stem cell. 21(6):747-760 . PubMed Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed Kim C, et al. 2019. Cell Rep. 29:2202. PubMed Glaros V, et al. 2021. Immunity. 54:2005. PubMed Bayik D, et al. 2020. Cancer Discov. 1.256944444. PubMed Quah B, et al. 2012. Cytometry A. 81:679. PubMed Karimi M, et al. 2015. Blood. 125:3655. PubMed Platteel A, et al. 2017. Vaccine.. 10.1016/j.vaccine.2017.10.044. PubMed Marcus A et al. 2018. Immunity. 49(4):754-763 . PubMed Krueger CC, et al. 2019. Front Immunol. 10:1831. PubMed Sharma S, et al. 2021. Pathophysiology. 28:501. PubMed Lim JE, et al. 2022. Front Oncol. 12:1045016. PubMed Murakami K, et al. 2021. Cell Reports. 34(1):108579. PubMed Huang D, et al. 2020. Nat Commun. 4.520833333. PubMed LM S, et al. 2016. Cell Rep. 16(12): 3286-96. PubMed Moutuou MM, et al. 2020. Methods Mol Biol. 2111:267. PubMed Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed Suan D et al. 2017. Immunity. 47(6):1142-1153 . PubMed Kretschmer L, et al. 2020. Nat Commun. 0.536805556. PubMed Ma K, et al. 2022. iScience. 25:104347. PubMed Wang X, et al. 2021. EMBO J. 40:e105926. PubMed Yuan X, et al. 2017. Elife. 6:e29540. PubMed Lee SC et al. 2018. Cancer cell. 34(2):225-241 . PubMed Lamb T, et al. 2022. Toxics. 10:. PubMed Zeis P, et al. 2020. Immunity. 53:775. PubMed X X, et al. 2016. J Immunol . 197: 1683-1691. PubMed Muri J, et al. 2020. Cell Reports. 29(9):2731-2744.e4.. PubMed Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed Zhu YP et al. 2018. Cell reports. 24(9):2329-2341 . PubMed Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed Mujal AM, et al. 2022. Cancer Immunol Res. 10:403. PubMed Gundra UM, et al. 2017. Nat Immunol. 1.195833333. PubMed Ehrens A, et al. 2021. Cell Reports. 34(2):108621. PubMed
RRID: AB_893348 (BioLegend Cat. No. 110727) AB_893346 (BioLegend Cat. No. 110728)
Structure: Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution: All hematopoietic cells except mature erythrocytes and platelets of the CD45.1 strain of mice
Function: Phosphatase, T and B cell activation
Ligand/Receptor: Galectin-1, CD2, CD3, CD4
Biology Area: Cell Biology, Immunology, Inhibitory Molecules, Neuroscience, Neuroscience Cell Markers
Molecular Family: CD Molecules
Antigen References: 1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85. 3. Kishihara K, et al. 1993. Cell 74:143. 4. Pulido R, et al. 1988. J. Immunol. 140:3851.
Gene ID: 19264
UniProt: View information about CD45.1 on UniProt.org
Clone: A20
Regulatory Status: RUO
Other Names: T200, Ly-5.1, LCA
Isotype: Mouse (A.SW) IgG2a, κ
Q: How stable is PerCP/Cyanine5.5 tandem as compared to PerCP alone?
A: PerCP/Cyanine5.5 is quite photostable and also better than PerCP alone in withstanding fixation.